September 8, 2025 4:38pm

As the cell and gene therapy sector tanked after multiple positive closes in September and worker confidence data in finding a new job hit a record LOW!

After writing on Friday’s closing bell: ‘be ready for "uncle algo and his electronic trading dwarfs" to come over for a short visit next week as the "frig" is full!’ and as I wrote this a.m. Monday, “time to “shade” your portfolio’s stress from inflation data and Fed’s upcoming policy meeting”

Remember, “The sector is what it is, until it isn’t, even if it doesn’t seem to be, it yet will be.”  Never leave an investor uninformed!  

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in your portfolio for the short-term

 

Monday’s RegMed Investors’ (RMi) pre-open: On deck … https://www.regmedinvestors.com/articles/14095

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Monday: The Dow closed UP +114.09 points or +0.25%, the S&P closed UP +13.65 points or +0.21% while the Nasdaq closed UP +98.311 points or +0.45%

  • Theme of the session, watch and wait for data-heavy week

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy

  • The New York Fed’s monthly Survey of Consumer Expectations indicated a 44.9% probability of finding another job after losing their current one, the lowest in the survey’s history. Expectations that the unemployment rate will be higher a year from now rose to 39.1%, up 1.7% from July.

Monday’s my (40) covered sector’s advance/decline line opened negative with 8 incliners, 32 decliners and 0 flats ending with a negative close of 10 incliners, 28 decliners and 2 flats

Metrics:  Monday, the IBB was down -0.91%, the XBI was down -1.04% while the VIX was up +0.06 points or +0.40% at 15.24

 

Q3 – 1 holiday, 2 negative and 3 positive closes

  • August – 12 negative and 9 positive closes
  • July – 1 market holiday, 13 positive and 9 negative closes

 

Monday Closing UP (10 of 10) 

  • Alnylam Pharmaceuticals (ALNY +$3.03 after Friday’s -$1.54),
  • Prime Medicine (PRME +$0.17),
  • Harvard Apparatus RT (OTCQB: HRGN +$0.17 after Friday’s -$0.08))
  • Mesoblast (MESO +$0.16 after Friday’s +$0.87),
  • AxoGen (AXGN +$0.06),
  • Cellectis SA (CLLS +$0.06),
  • MiMedx (MDXG +$0.03),
  • Editas Medicine (EDIT +$0.03),
  • Voyager Therapeutics (VYGR +$0.02),
  • Adverum Biotechnologies (ADVM +$0.02),

Flat (2)

  • Compass Therapeutics (CMPX),
  • IQV Holdings (IQV)

Monday’s Closing DOWN (10 of 28): 

  • BioNTech SE (BNTX -$9.80 after Friday’s +$8.96),
  • Lenz Therapeutics (LENZ -$2.35 after Friday’s +$2.06),
  • Arrowhead Pharmaceuticals (ARWR -$1.91),
  • Sarepta Therapeutics (SRPT -$1.11),
  • Beam Therapeutics (BEAM -$0.94),
  • Vertex Pharmaceuticals (VRTX -$0.87 after Friday’s -$0.81),
  • Vericel (VCEL -$0.83),
  • CRISPR Therapeutics (CRSP -$0.76 after Friday’s +$2.12),
  • WVE Life Sciences (WVE -$0.71),
  • uniQure NV (QURE -$0.52),

 

The BOTTOM LINE:  More of the … WHYs …

“US stocks moved higher on Monday as investors set their sights on inflation data later this week to provide a reality check on the chances of a jumbo interest-rate cut next week.” <Yahoo Finance>

The cell and gene therapy seems to be currently residing and possibly staying in a … catalyst vacuum with more downside drift potentially coming into the markets which is … flirting with all-time highs in a … seasonally weak period.

In the New York Fed’s August survey of consumer expectations, respondents “perceived” probability of landing a job after losing their current position fell to 44.9% — the lowest measure in the survey's history going back to June 2013.

From Monday’s morning post, “In the week, Wednesday’s PPI and wholesale inventories and Fed Chair Powell’s press conference at 2:30 p.m., ET, Thursday's CPI (inflation data) initial jobless claims, the weekly update on mortgage rates will be closely watched. Friday’s consumer sentiment could offer uncertain mix of upcoming inflation pressures; followed by None on Friday – Thankfully.

… unless there’s some event out of left field with regard to tariffs or trade.

September: understand the “flow” …

  • 9/8 – Monday closed negative with 10 positive, 28 negative and 2 flats
  • 9/5 - Friday closed positive with 35 positive, 5 negative and 0 flat
  • 9/4 – Thursday closed negative with 17 positive, 21 negative and 2 flats
  • 9/3 - Wednesday closed positive with 22 positive, 16 negative and 2 flats
  • 9/2 -Tuesday closed positive with 22 positive, 18 negative and 0 flat
  • 9/1 -Monday was a holiday

Welcome to my world of defining the “grey’ in our universe!

  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Monday: Alnylam Pharmaceuticals (ALNY), Prime Medicine (PRME) and Harvard Apparatus RT (OTCQB: HRGN)
  • Friday: BioNTech (BNTX), IQVIA Holdings (IQV) and Beam Therapeutics (BEAM)

The worst three (3) in the session: 

  • Monday: BioNTech (BNTX), Lenz Therapeutics (LENZ) and Arrowhead Pharmaceuticals (ARWR)
  • Friday: Alnylam Pharmaceuticals (ALNY), Vertex Pharmaceuticals (VRTX) and Precigen (PGEN)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.